Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
A director of Vertex Pharmaceuticals (VRTX) reported a change in ownership of the company’s common stock. On 11/19/2025, the director recorded a transaction in which 800 shares of Vertex common stock were disposed of, coded as transaction type “G”. The shares were reported at a price of $0, indicating no cash consideration was recorded for this movement of shares in the form.
After this transaction, the director beneficially owns 6,315 shares of Vertex common stock in direct ownership. The filing is made on Form 4, which is used to report changes in insider ownership for directors, officers, and significant shareholders.
Vertex Pharmaceuticals (VRTX) executive Mark Atkinson reported a planned stock sale. As Executive Vice President and Chief Technical Operations Officer, he filed a Form 4 showing the sale of 2,500 shares of Vertex common stock on 11/17/2025 at a price of $434.58 per share.
After this transaction, he beneficially owned 16,852 shares directly. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on 08/11/2025, meaning the trades were pre-arranged under SEC rules designed to allow insiders to sell shares according to a preset plan.
Vertex Pharmaceuticals (VRTX) reported insider transactions by its Executive Chairman and Director, Dr. Jeffrey Leiden. On 11/13/2025 and 11/14/2025, he exercised stock options to acquire Vertex common stock at exercise prices of $91.05 and $86.52 per share, then sold portions of the shares in the open market.
Reported sales included 18,528 shares at a weighted average price of $440.22, 1,160 shares at $441.05, 32,234 shares at $440.30, and 21,330 shares at $441.35, plus smaller additional amounts. After these transactions, Dr. Leiden beneficially owned 24,026 Vertex shares directly and 440 shares through a 401(k), along with vested stock options. The filing notes the trades were made under a company-approved Rule 10b5-1 trading plan entered into on 8/6/2025.
Vertex Pharmaceuticals (VRTX) reported higher Q3 results. Total revenues were $3,076.4 million, up from $2,771.9 million a year ago, driven by TRIKAFTA/KAFTRIO at $2,653.6 million and ALYFTREK at $247.0 million. Net income rose to $1,082.9 million with diluted EPS of $4.20 versus $4.01. Operating income was $1,186.2 million.
Year-to-date, total revenues reached $8,811.3 million and net income was $2,762.1 million. U.S. product revenues were $1,976.3 million; Europe contributed $836.9 million. “Other revenues” of $30.7 million year-to-date included upfront payments related to povetacicept regional agreements. The balance sheet remained strong with cash and cash equivalents of $4,939.6 million and long-term marketable securities of $5,722.8 million. The company repurchased 4.5 million shares for $1.9 billion year-to-date and has $3.5 billion remaining under its 2025 authorization. CASGEVY and JOURNAVX contributed $16.9 million and $19.6 million, respectively, within other product revenues in Q3.
Vertex Pharmaceuticals Incorporated filed a current report to note that it has released its latest quarterly and year-to-date financial results. On November 3, 2025, the company issued a press release reporting consolidated financial results for the three and nine months ended September 30, 2025. That press release is furnished as Exhibit 99.1 to this report and is incorporated by reference, but is not treated as "filed" for liability purposes under the Exchange Act.
Vertex Pharmaceuticals (VRTX) reported an insider transaction by a director on a Form 4. On 10/15/2025, the director acquired 86.825 deferred stock units (Transaction Code A) at $410.31 per unit.
Each deferred stock unit represents one share of common stock and will be settled in stock upon the earliest of termination of board service, a change of control, disability, or death. Following the transaction, 2,638.332 derivative securities were beneficially owned directly.
Vertex Pharmaceuticals (VRTX) reported an insider equity award. Director Mr. Sachs acquired 115.766 deferred stock units on 10/15/2025 at $410.31 per unit. Following the transaction, he beneficially owns 15,457.433 derivative securities directly.
Each deferred stock unit represents one share of common stock and is settled in stock upon the earliest of termination of board service, a change of control, or the director’s disability or death.
Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), reported insider dispositions under a company-approved Rule 10b5-1 trading plan entered on 02/24/2025. On 10/01/2025 he disposed of 1,259 shares at $400, reducing his beneficial ownership to 16,347 shares, and on 10/02/2025 he sold 694 shares at $404.21, leaving 15,653 shares beneficially owned after the second transaction. The filing is signed by an attorney-in-fact on 10/03/2025.
Vertex Pharmaceuticals (VRTX) Form 144 notice reports a proposed sale of 694 shares of common stock through Fidelity Brokerage Services, with an approximate aggregate market value of $280,521.74 and an approximate sale date of 10/02/2025 on NASDAQ. The shares were acquired on 10/01/2025 by restricted stock vesting from the issuer and were paid as compensation. The filer reports no other sales in the past three months and makes the required representation that no undisclosed material adverse information is known.
Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals (VRTX), reported a sale of 266 shares of common stock on 08/27/2025 at a price of $386.69 per share, leaving her with 4,565 shares beneficially owned. The filing states the transaction was made pursuant to a company-approved Rule 10b5-1 trading plan entered on 05/27/2025. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The report discloses a single non-derivative sale and confirms the use of an affirmative-defense trading plan.